Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple
    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • ASP-1929-301 - Civantos Jr, Francisco

  • Investigator:
    Francisco Civantos Jr
    RCname Email

    		Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone 3052430124

    IRB: 20181096

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx
    Sponsor: RAKUTEN ASPYRIAN

    Enrolling Sites:

    Sylvester
    Title:

    ASP-1929-301 : A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician?s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
    Eligibility Criteria - NCT03769506 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin
    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:

    IRB: 20191076

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin
    Sponsor: EISAI

    Enrolling Sites:

    Sylvester
    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101
    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • EA6174 - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    		Coordinator:
    RCemailImg Carla Munevar
    RCphone 9542101170

    IRB: 20190337

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Other Skin
    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    EA6174: A Phase III Randomized Trial Comparing Adjuvant MK- 3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
    Eligibility Criteria - NCT03712605 *This information has been extracted from " www.clinicaltrials.gov"

  • IM-202 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    		Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180968

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Stomach,Lung
    Sponsor: IAB

    Enrolling Sites:

    Sylvester
    Title:

    IM-202 : A Randomized, Open-Label, Multicenter, Phase 1b/2 Trial Evaluating The Safety And Efficacy Of Intratumorally-Administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who are Candidates ForCPI Therapy
    Eligibility Criteria - NCT03735290 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue
    Sponsor: CP

    Enrolling Sites:

    Sylvester
    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • AST-008-102 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20180957

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Bones and Joints,Melanoma, skin
    Sponsor: EXICURE INC

    Enrolling Sites:

    Sylvester
    Title:

    AST-008-102 :A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
    Eligibility Criteria - NCT03684785 *This information has been extracted from " www.clinicaltrials.gov"

  • ATA129-NPC-202 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone 3052430124

    IRB: 20181013

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx
    Sponsor: Atara

    Enrolling Sites:

    Sylvester
    Title:

    ATA129-NPC-202 : An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum-pretreated, Recurrent/Metastatic Epstein Barr Virus Associated Nasopharyngeal Carcinoma
    Eligibility Criteria - NCT03769467 *This information has been extracted from " www.clinicaltrials.gov"

  • C3851001 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190114

    		SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Cervix Uteri,Other Endocrine System,Lung
    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester
    Title:

    C3851001: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics Of Escalating Doses Of PF-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, CervicalCancer And Bladder Cancer
    Eligibility Criteria - NCT03854227 *This information has been extracted from " www.clinicaltrials.gov"

  • ION-01-ALKS 4230 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:

    IRB: 20190573

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Larynx
    Sponsor: ALKERMES INC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1(Pembrolizumab) in Patients With Advanced or Recurrent Headand Neck Squamous Cell Cancer Currently on Treatment WithAnti-PD-(L)1 Without Having Achieved a Complete Remission
    Eligibility Criteria - NCT04144517 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20160656

    		SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Other Hematopoietic,Anus,Lung
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • EMR100036-002 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    		Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160382

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Breast,Cervix Uteri,Stomach,Lung
    Sponsor: EMD

    Enrolling Sites:

    Sylvester
    Title:

    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors
    Eligibility Criteria - NCT02516813 *This information has been extracted from " www.clinicaltrials.gov"

  • EA3163 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    		Coordinator:
    RCemailImg Lilly Sanchez
    RCphone 3052430974

    IRB: 20180505

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx
    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
    Eligibility Criteria - NCT03493425 *This information has been extracted from " www.clinicaltrials.gov"

  • NRG-HN004 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    		Coordinator:
    RCemailImg Lilly Sanchez
    RCphone 3052430974

    IRB: 20190349

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Larynx
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
    Eligibility Criteria - NCT03258554 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180909 - Thomas Giovana R

  • Investigator:
    Giovana R Thomas
    RCname Email

    		Coordinator:

    IRB: 20180909

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx
    Sponsor: VIGILANT BIOSCIENCES INC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    Clinical Evaluation of the OncAlert RAPID in Subjects presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making.
    Eligibility Criteria - NCT03239834 *This information has been extracted from " www.clinicaltrials.gov"